PEDIATRICS Vol. 92 No. 4 October 1993, pp. 519-523
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Messer, J.
Right arrow Articles by Matis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messer, J.
Right arrow Articles by Matis, J.

Early Treatment of Premature Infants With Recombinant Human Erythropoietin

Jean Messer MD1, Joseph Haddad MD1, Lionel Donato MD1, Dominique Astruc MD1, and Jacqueline Matis MD1

1 The Service de Neonatologie, University Hospital of Strasbourg, Hôpital de Hautepierre, Strasbourg, France.

Objectives. The specific objectives of this study were (1) to assess the safety and efficacy of recombinant human erythropoietin (rhEPO) in reducing postnatal hemoglobin decline in premature infants of less than 33 weeks' gestation, and thus reducing the need for transfusion; and (2) to determine the optimal dosage of rhEPO.

Materials and methods. Three groups of premature infants of less than 33 weeks' gestation were treated with rhEPO: group 1 (n = 10) received 300 U/kg per week; group 2 (n = 11), 600 U/kg per week; and group 3 (n = 10), 900 U/kg per week. These three groups were compared to a reference group of 20 infants of the same gestational age and birth weight. Treatment started on the 10th day of life and lasted 6 weeks. All infants were given oral iron and vitamin E supplements.

Results. Treated infants had significantly higher reticulocyte counts, and the effect was dose dependent (P = .009). Postnatal decline of hemoglobin and hematocrit was lessened in the treated groups; the percent of decrease of hemoglobin and hematocrit was significantly reduced in the treated infants at 35 days of age (P = .0025 and P = .0036, respectively). The need for blood transfusion was also reduced in the rhEPO-treated groups: 19% of treated vs 45% of reference infants received transfusions, and the treated infants received less blood. Serum iron and transferrin saturation percentage dropped significantly during the study and a dose-dependent relationship in treated infants was displayed, suggesting high iron consumption (P = .0008 and P = .006, respectively). No dose effect on hemoglobin level and the need for blood transfusion was found, possibly because of the higher degree of illness severity and iron consumption in groups 2 and 3. No side effects related to rhEPO therapy were observed.

Conclusions. It is concluded that rhEPO therapy is safe in premature babies when given in the three dosages used in this study; in addition, it enhances erythropoiesis and reduces the need for blood transfusions. rhEPO therapy seems more efficient when given in higher dosages; however, illness severity and iron consumption represent major limiting factors. Controlled, randomized studies are warranted to confirm these data and to determine precise modalities and indications of rhEPO therapy in premature infants.

Key Words: neonate • anemia • prematurity • erythropoietin • transfusion • iron metabolism

Submitted on February 16, 1993
Accepted on April 5, 1993




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
S. Feinstein, C. Rinat, R. Becker-Cohen, E. Ben-Shalom, S. B. Schwartz, and Y. Frishberg
The outcome of chronic dialysis in infants and toddlers--advantages and drawbacks of haemodialysis
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1336 - 1345.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
A Pathak, P Roth, J Piscitelli, and L Johnson
Effects of vitamin E supplementation during erythropoietin treatment of the anaemia of prematurity
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2003; 88(4): F324 - F328.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. W. Fisher
Erythropoietin: Physiology and Pharmacology Update
Experimental Biology and Medicine, January 1, 2003; 228(1): 1 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
S. Nazir, R. L. Peverini, D. D. Deming, A. O. Hopper, and N. R. Vyhmeister
Comparison of 2 Iron Doses in Infants Receiving Recombinant Human Erythropoietin Therapy
Arch Pediatr Adolesc Med, June 1, 2002; 156(6): 540 - 544.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. Donato, N. Vain, P. Rendo, N. Vivas, L. Prudent, M. Larguía, J. Digregorio, C. Vecchiarelli, R. Valverde, C. García, et al.
Effect of Early Versus Late Administration of Human Recombinant Erythropoietin on Transfusion Requirements in Premature Infants: Results of a Randomized, Placebo-Controlled, Multicenter Trial
Pediatrics, May 1, 2000; 105(5): 1066 - 1072.
[Abstract] [Full Text]

Home page
 PediatricsHome page
M. S. Brown and J. F. Keith III
Comparison Between Two and Five Doses a Week of Recombinant Human Erythropoietin for Anemia of Prematurity: A Randomized Trial
Pediatrics, August 1, 1999; 104(2): 210 - 215.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
V. P Carnielli, R. Da Riol, and G. Montini
Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1998; 79(1): 44F - 48.
[Abstract] [Full Text]

Home page
 Stem CellsHome page
B. Meister, H. Maurer, B. Simma, H. Kern, H. Ulmer, A. Hittmair, and F.-M. Fink
The Effect of Recombinant Human Erythropoietin on Circulating Hematopoietic Progenitor Cells in Anemic Premature Infants
Stem Cells, September 1, 1997; 15(5): 359 - 363.
[Abstract] [Full Text]

Home page
 NEJMHome page
D. Beck, A. Calame, E. Masserey, V. P. Carnielli, R. D. Riol, G. Montini, J. N. van den Anker, G. Montini, V. P. Carnielli, R. F. Maier, et al.
Recombinant Erythropoietin in Very-Low-Birth-Weight Infants
N. Engl. J. Med., September 8, 1994; 331(10): 676 - 678.
[Full Text]

Home page
 NEJMHome page
R. G. Strauss
Erythropoietin and Neonatal Anemia
N. Engl. J. Med., April 28, 1994; 330(17): 1227 - 1228.
[Full Text]